Mira Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2026
Filed with the SEC on Aug 12, 2026 and accepted by EDGAR at Aug 12, 2026, 20:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2026-04-01 to 2026-06-30 | $705.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2026-01-01 to 2026-06-30 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Net income | 3 months2026-04-01 to 2026-06-30 | −$1.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2026-01-01 to 2026-06-30 | −$2.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-04-01 to 2026-06-30 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2026-01-01 to 2026-06-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-04-01 to 2026-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2026-01-01 to 2026-06-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2026-01-01 to 2026-06-30 | −$2.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2026-06-30 | $3.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-06-30 | $8.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-06-30 | $8.2m | us-gaap:Assets |
| Current liabilities | At period end2026-06-30 | $40.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-06-30 | $40.8k | us-gaap:Liabilities |
| Shareholders' equity | At period end2026-06-30 | $8.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-26-037366. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.